查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198064

产后出血设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Postpartum Hemorrhage Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内（2022 年至 2027 年），产后出血设备市场预计将以 5.1% 的复合年增长率增长。

COVID-19 大流行最初对产后出血设备市场产生了重大影响。 美国妇产科学院 2022 年的一份报告发现，与非孕妇相比，有症状的患有 COVID-19 的孕妇更有可能需要重症监护或需要呼吸机（用于呼吸支持），也更有可能死于疾病。 然而，孕妇患重病或死亡的总体风险很小。 虽然 COVID-19 的爆发对其前身的市场增长产生了负面影响，但妊娠并发症的数量正在增加，推动了对产后出血设备的需求，以治疗患者和挽救母亲的生命。它正在增加并促进行业的发展。

此外，妊娠并发症发生率的增加是推动产后止血装置需求的主要因素，有助于市场的增长。 妇产科杂誌上发表的 2021 年公告解释了怀孕期间贫血的不人道之处。 缺铁和大量出血是孕期和产后贫血的最常见原因。 怀孕期间对铁的需求增加，未能维持足够的铁水平会对母亲和胎儿产生不利影响。 预计这些因素将促进产后止血装置的采用并促进市场增长。

此外，市场参与者正在製定营销策略，例如已推出产品的併购。 例如，默克公司计划在 2021 年剥离 Organon，这将通过促进更安全的分娩来解决孕产妇健康方面未得到满足的医疗需求，从而实现其致力于增强女性健康的承诺。宣布收购 Aridia Health 代表 Aridia 的技术 Jada System 旨在诱导自然子宫收缩，以防止分娩后出血过多。 美国食品和药物管理局根据该公司关键的 PEARLE IDE 试验结果，于 2020 年 8 月批准了 Jada System 的 510(k) 许可。 全球健康投资基金和 AXA IM Artz 通过其影响力投资战略成为 Aridia 的领先机构投资者。 这些基金是社会影响基金，投资于创新技术，这些技术可以产生有吸引力的财务回报，同时有助于解决世界上一些主要的公共卫生问题。 此外，2021 年 9 月，Stryker 宣布收购医疗设备公司 Gauss Surgical，该公司创建了 TritonTM，这是一个人工智能驱动的实时术中出血监测平台。 Triton 通过更早发现出血和更早干预，在产科和外科手术中显示出优势。

此外，主要的市场竞争对手正在通过新产品发布和战略举措对行业增长产生积极影响。 例如，2022 年 3 月，Baymatob 的可穿戴设备完成增资，推进其救生劳动监测设备。 Baymatob 的可穿戴设备 Oli 使用创新的传感器技术和 AI 解释来检测产后出血开始前分娩过程中的 PPH 滞留情况。

因此，由于上述因素，所研究的市场预计在分析期内会出现增长。 然而，缺乏训练有素的专业人员正在製约产后出血市场的增长。

产后止血器市场趋势

预计在预测期内子宫填塞装置将大幅增长

子宫球囊填塞是一种治疗难治性产后出血的非手术疗法。 在确认产后出血并进行药物治疗后，它可用于填塞子宫出血而无需手术干预。 充满液体后，将塌陷的球囊置于子宫内，使其顺应宫腔形状，填塞子宫出血。 导管的中央内腔便于引流，并用于检测气囊水平以上发生的出血。 子宫填塞是通过填塞出血子宫表面来控制产后出血的一种安全、简单、实用的方法。

2021 年在 MDLinx 上发表的一项研究描述了真空引导子宫压塞装置的未来进展，该装置可对子宫施加负压、收缩出血腔并关闭渗漏血管。 这种低成本、无创的方法在其他治疗选择有限的发展中国家可能很有价值。 因此，子宫球囊填塞带来的好处可能会增加目标人群对这些产品的采用，最终推动市场的增长。

此外，2021 年，发表在 BMJ Case Reports 上的一篇研究论文发现，避孕套填塞可以显着降低与产后出血相关的孕产妇发病率和死亡率。 该研究显示了良好的结果，解释了避孕套填塞可以节省患者的时间和生命。

如2021年发表在Pubmed Central上的一篇论文，论证了使用Bakriballoon加宫颈粘连术预防和治疗妊娠晚期产后出血并发急性主动脉夹层是令人满意的。你得到了结果。

因此，由于上述因素，预计子宫填塞部分在预测期内将出现显着的正增长。

预计在预测期内北美将主导产后止血器市场

在预测期内，北美的产后止血装置市场份额最大。 该地区的出现可归因于美国和北美其他地区产后出血或分娩的增加。 2020 年英联邦基金会的一份出版物《美国的孕产妇死亡率和孕产妇护理与其他 10 个发达国家相比》发现，美国的孕产妇死亡率在发达国家中最高。 在美国，以出生后第一年计算，大约三分之一的妊娠相关死亡发生在妊娠期间。 此外，北美产后出血市场受到医疗基础设施进步和医疗成本上升的推动。 对复杂的产后出血治疗的认识不断提高也推动了市场的发展。

此外，促进产后出血市场增长的其他因素包括主要产品的批准、妊娠并发症上升、死亡率和製造商在国内的存在。 例如：2021 年 9 月，美国食品和药物管理局批准了 Jada 系统，这是一种用于控制和治疗产后异常子宫出血或需要保守治疗时出血的医疗器械。 作为 2020 年 8 月 PEARLE IDE 调查（标识符：NCT02883673）的结果，发现 Jada 可有效预防产后出血（主要终点：非手术治疗、二次治疗，94.3%（n=100/106，P. 001）首次获批。 由于这些原因，北美地区的市场有望扩大。

产后出血设备市场竞争对手分析

由于多家公司在全球和区域运营，产后出血设备市场是一个分散的市场。 竞争格局包括对几家具有市场份额的知名国际和本地公司的分析。 包括 Bactiguard、Cook Medical、Utah Medical Products, Inc.、Teleflex Incorporated 和 Organon & Co 等公司。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 妊娠并发症（贫血）的发生率增加，例如胎盘早剥、多胞胎和子宫内翻
    • 增加政府举措并提高认识
  • 市场製约因素
    • PPH 设备成本高，缺乏训练有素的专业人员
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按产品类型
    • 非气动防震服
    • 预填充注射系统
    • 子宫填塞装置
  • 最终用户
    • 医院
    • 诊所
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Bactiguard
    • Cook Medical
    • Utah Medical Products, Inc.
    • Teleflex Incorporated
    • Sinapi Biomedical
    • Zoex Niasg
    • 3D Stone Design Inc.
    • Organon & Co.
    • Laborie（Clinical Innovations）
    • Becton, Dickinson and Company
    • Boen Healthcare Co., Ltd

第7章 市场机会与今后动向

简介目录
Product Code: 90973

The postpartum hemorrhage devices market is expected to register a CAGR of 5.1% over the forecast period (2022-2027).

The COVID-19 pandemic significantly impacted the market for postpartum hemorrhage devices at the beginning. The American College of Obstetricians and Gynaecologists 2022 reports that pregnant women who have COVID-19 and show symptoms are more likely than nonpregnant women with COVID-19 symptoms to require intensive care, require a ventilator (for breathing support), or die as a result of the illness. Despite this, pregnant women's overall risk of serious disease and death is minimal. The COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the number of pregnancy complications has increased, and so has the demand for postpartum hemorrhage devices to treat patients and save the lives of mothers, assisting in the advancement of the industry.

Further, the increasing rate of complications in pregnancies is a major factor driving the demand for postpartum hemorrhage devices, thereby contributing to market growth. The 2021 bulletin published in the journal of Obstetrics and Gynecology explains the atrocities of anemia during pregnancy. Iron deficiency and abrupt blood loss are the two most common causes of anemia during pregnancy and puerperium. During pregnancy, iron requirements rise, and failing to maintain adequate iron levels can have negative maternal-fetal implications. Such factors will likely boost the adoption of postpartum hemorrhage devices, thereby contributing to market growth.

Moreover, market players are involved in marketing strategies like mergers and acquisitions of products launched. For instance, in 2021, Merck announced the acquisition of Alydia Health on behalf of its planned spinoff of Organon, which implements dedication to enhancing women's health through addressing unmet medical needs in maternal health by facilitating safer delivery. The Jada System, Alydia's technology, is designed to induce natural uterine contractions to prevent excessive bleeding after childbirth. The United States Food and Drug Administration granted Alydia 510(k) clearance (marketing authorization) for the Jada System in August 2020, based on the company's pivotal PEARLE IDE Study results. The Global Health Investment Fund and AXA IM Alts, through its Impact Investing Strategy, are Alydia's lead institutional investors. They are social impact funds that invest in innovative technologies that can generate attractive financial returns while helping address major public health issues worldwide. Additionally, in September 2021, Stryker announced the acquisition of Gauss Surgical, a medical device firm that created TritonTM, an artificial intelligence-powered platform for real-time blood loss monitoring during surgery. Triton has shown advantages in maternity and surgical care by detecting hemorrhage earlier and intervening sooner.

Furthermore, prominent market competitors favorably impact the industry's growth through new product releases and strategic efforts by prominent market competitors. For example, in March 2022 Baymatob's wearable devices completed capital rise to advance life-saving labor monitoring devices. Baymatob's wearable device Oli uses innovative sensor technology and AI interpretation to detect a Pending PPH during labor before postpartum bleeding starts.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the lack of trained professionals restrains the postpartum hemorrhage market growth.

Postpartum Hemorrhage Devices Market Trends

Uterine Tamponade Devices are Expected to Witness a Positive Growth Over the Forecast Period

Uterine balloon tamponade is a non-surgical treatment for refractory postpartum bleeding. It can be used to tamponade uterine bleeding without operational intervention once postpartum hemorrhage has been recognized, and medicinal care has been given. When filled with fluid, the collapsed balloon is put into the uterus, which adapts to the shape of the uterine cavity to tamponade uterine hemorrhage. The catheter's central lumen facilitates drainage and is meant to detect any bleeding that occurs above the balloon's level. By delivering tamponade to the bleeding, uterine surface, uterine packing is a safe, straightforward, and practical approach to controlling postpartum hemorrhage.

The study published in MDLinx in 2021 explains the future advances in vacuum-induced uterine tamponade devices, which impart negative pressure to the uterus, causing the bleeding cavity to contract and leaking blood vessels to close. This low-cost, noninvasive method could be precious in developing nations where other treatment options are limited. Hence, owing to the advantages offered by uterine balloon tamponade, the adoption of these products is likely to increase among the target population, ultimately driving the market growth.

Furthermore, in 2021, a research article published in BMJ Case Reports found that condom tamponade can significantly reduce maternal morbidity and mortality associated with postpartum hemorrhage. In that study, they explain that condom tamponade saves both time and life of patients with positive results.

As per the article published in 2021 in Pubmed Central, substantiating the use of Bakri balloon plus cervical cerclage for the prevention and treatment of postpartum hemorrhage in late pregnancy complicated with acute aortic dissection provides satisfactory results.

Therefore, the uterine tamponade segment is expected to witness significant positive growth over the forecast period due to the abovementioned factors.

North America is Expected to Dominate the Postpartum Hemorrhage Devices Market Over the Forecast Period

North America had the largest market share for postpartum hemorrhage devices during the forecast period. The emergence of this region can be attributed to an increase in postpartum bleeding or hemorrhage in the United States and the rest of North America. The article published in 2020 in The Commonwealth Fund publication, "Maternal Mortality and Maternity Care in the United States Compared to 10 Other Developed Countries," explains that the United States has the highest maternal mortality rate among developed countries. Approximately one-third of all pregnancy-related deaths in the United States occur during pregnancy, as measured up to one year after birth. Moreover, the Postpartum Hemorrhage market in North America is being driven by advancements in healthcare infrastructure and rising healthcare spending. Also, increased awareness of sophisticated postpartum hemorrhage treatments grows the market.

Furthermore, the other factors involved in the growth of the postpartum hemorrhage market include key product approvals, increased pregnancy complications, and mortality rate or manufacturer's presence in the country. For Instance, in September 2021, the Food and Drug Administration approved Jada System, a medical device designed to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative therapy is required. Jada was approved for the first time in August 2020, based on findings from the PEARLE IDE research (Identifier: NCT02883673), which found that the device was 94.3 percent effective (n=100/106; P.001) in preventing postpartum hemorrhage (primary endpoint; defined as the avoidance of nonsurgical, second-line or surgical intervention to control uterine bleeding after the use of the Jada System). As a result of the factors above, the studied market is expected to increase in the North American region.

Postpartum Hemorrhage Devices Market Competitor Analysis

The postpartum hemorrhage devices market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold the market shares and are well known. Include Bactiguard, Cook Medical, Utah Medical Products, Inc., Teleflex Incorporated, and Organon & Co., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Occurrence of Conditions like Placental Abruption, Multiple Pregnancy and Inverted Uterus and other pregnancy complications (Anemia)
    • 4.2.2 Inflated Number of Government Initiatives Coupled with Increased Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of PPH Devices & Lack of Trained Proffesionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Non-Pneumatic Anti-Shock Garment
    • 5.1.2 Prefilled Injection System
    • 5.1.3 Uterine Tamponade Devices
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Clinics
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bactiguard
    • 6.1.2 Cook Medical
    • 6.1.3 Utah Medical Products, Inc.
    • 6.1.4 Teleflex Incorporated
    • 6.1.5 Sinapi Biomedical
    • 6.1.6 Zoex Niasg
    • 6.1.7 3D Stone Design Inc.
    • 6.1.8 Organon & Co.
    • 6.1.9 Laborie (Clinical Innovations)
    • 6.1.10 Becton, Dickinson and Company
    • 6.1.11 Boen Healthcare Co., Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS